Innoviva, Inc. (INVA) News
Filter INVA News Items
INVA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INVA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest INVA News From Around the Web
Below are the latest news stories about INNOVIVA INC that investors may wish to consider to help them evaluate INVA as an investment opportunity.
Innoviva's (NASDAQ:INVA) investors will be pleased with their 26% return over the last five yearsIf you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to... |
Innoviva enters distribution, license agreement with Basilea for ZevteraInnoviva (INVA) announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica for the commercialization of Zevtera, an advanced-generation cephalosporin antibiotic, in the United States. In April, the FDA approved Zevtera for three specific treatment indications, and it is the only FDA-approved methicillin-resistant Staphylococcus aureus, or MRSA, cephalosporin antibiotic for treating adult patients with Staphylococcus aureus bloodstream infections and |
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)BURLINGAME, Calif., December 16, 2024--Innoviva Specialty Therapeutics, Inc., ("IST") a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), for the commercialization of Zevtera® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the United States. |
Innoviva to Participate in the Citi 2024 Global Healthcare ConferenceBURLINGAME, Calif., November 26, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Citi 2024 Global Healthcare Conference in Miami, FL on Thursday, |
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial ActivityEverest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that data on its critical-care, anti-infective product, eravacycline (XERAVA®), was recently presented in Los Angeles, California at IDWeek 2024. Among the findings, two in vitro study results further demonstrated the broad and consistent antimicrobial activity of eravacycline. |
Innoviva to Participate in the UBS Global Healthcare ConferenceBURLINGAME, Calif., November 12, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at |
Innoviva Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$1.26 in 3Q 2023)Innoviva ( NASDAQ:INVA ) Third Quarter 2024 Results Key Financial Results Revenue: US$89.5m (up 33% from 3Q 2023). Net... |
Innoviva: Q3 Earnings SnapshotBURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported earnings of $1.2 million in its third quarter. |
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company ProgressBURLINGAME, Calif., November 06, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. |
Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?Most readers would already be aware that Innoviva's (NASDAQ:INVA) stock increased significantly by 17% over the past... |